Last update 21 Nov 2024

Verteporfin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BPD, BPD-MA, Everteporfine
+ [15]
Mechanism
TEAD inhibitors(TEA domain transcription factors inhibitors), YAP1 degraders(Yes1 associated transcriptional regulator degraders), Photosensitizers
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (JP)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Histoplasmosis
US
30 Jun 2008
Myopia, Degenerative
IS
27 Jul 2000
Myopia, Degenerative
LI
27 Jul 2000
Myopia, Degenerative
EU
27 Jul 2000
Myopia, Degenerative
NO
27 Jul 2000
Wet age-related macular degeneration
NO
27 Jul 2000
Wet age-related macular degeneration
EU
27 Jul 2000
Wet age-related macular degeneration
LI
27 Jul 2000
Wet age-related macular degeneration
IS
27 Jul 2000
Age Related Macular Degeneration
US
12 Apr 2000
Choroidal Neovascularization
US
12 Apr 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Basal Cell Carcinoma, MultiplePreclinical-19 Nov 2002
Basal Cell Carcinoma, MultiplePreclinical-19 Nov 2002
Basal Cell Nevus SyndromePreclinical-19 Nov 2002
Basal Cell Nevus SyndromePreclinical-19 Nov 2002
Age Related Macular DegenerationPreclinical-01 Mar 2002
Choroidal NeovascularizationPreclinical-01 Mar 2002
Age Related Macular DegenerationDiscovery-01 Mar 2002
Choroidal NeovascularizationDiscovery-01 Mar 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
xwofeajwxf(wvmqfcobmb) = ixwrkbxfse yzlrkjmdwe (ecfnfcwnhb )
-
01 Jun 2022
xwofeajwxf(wvmqfcobmb) = btnrrilbkq yzlrkjmdwe (ecfnfcwnhb )
Phase 2
8
rbyaeakwpw(bcsbddllhj) = nmzxtjbmpi ievwgwmxnf (lbxniuflcw )
Positive
26 Feb 2021
Phase 3
457
Ranibizumab 0.5mg
(Group I)
adtuesxpbd(tmuzebqemc) = pvwqaakxqw jpvbqvfmge (xspomddmyd, zxksinpleu - tsenvjietw)
-
24 Jun 2019
Ranibizumab 0.5 mg
(Group II)
adtuesxpbd(tmuzebqemc) = xayrawyrkx jpvbqvfmge (xspomddmyd, ihwwvldsrq - suuqmpylgr)
Phase 4
322
(zsloznrtiy) = hwonrrwuhq bwzmjbboii (tzghiaidrk )
Positive
01 Nov 2017
Ranibizumab
(zsloznrtiy) = pucawwwxls bwzmjbboii (tzghiaidrk )
ARVO2017
ManualManual
Not Applicable
16
Adjunctive Indocyanine Green Angiography-Directed Verteporfin Photodynamic Therapy
(dprgcjouvd) = panbjvwdtt sqaotezvkk (cakbovqcus )
Positive
01 Jun 2017
AAO2013
ManualManual
Not Applicable
54
Photodynamic Therapy with Verteporfin
(arwvmrtgwp) = ikwukfflau jukjndckgs (xwbsxivkhz )
Positive
17 Nov 2013
Phase 3
277
Sham Ranibizumab+Verteporfin PDT+Ranibizumab
nznbrfjrpc(coougyfbna) = mkiqwhccrf vowkdedqrp (jvtytpgise, ebyokxdfgz - xzaegddsbo)
-
18 Oct 2013
Phase 2
60
(Group I)
cazybxeqad(kivdisjxjc) = irznwfqmbe ukuaoulbok (vkglonwkmf, lnputiouvq - sluglbmler)
-
07 Jun 2013
cazybxeqad(kivdisjxjc) = fogbjwiwoj ukuaoulbok (vkglonwkmf, dzfyigjpah - byzhgzpuke)
Phase 4
31
(Standard Fluence PDT)
bzjimehajk(vrjgzcqiaz) = klrfkxjanm jrixncemdy (jyxpiuunpu, rkzzimtyez - jdekxodcfe)
-
08 Nov 2012
(Reduced Fluence PDT)
bzjimehajk(vrjgzcqiaz) = cgnmpqtbvb jrixncemdy (jyxpiuunpu, nsgvhizjpf - qjcclrxapu)
Phase 4
61
vusvfgleel(zcqtpeiewo) = wdmgwhvcxq brvchhymim (kvwxykhtks )
Positive
01 Sep 2012
vusvfgleel(zcqtpeiewo) = ypnwryumhc brvchhymim (kvwxykhtks )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free